Anakinra
Immune Effector Cell Associated Neurotoxicity Syndrome
Ann & Robert H Lurie Children's Hospital of Chicagoprotein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Immune Effector Cell Associated Neurotoxicity Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Teclistamab Jack Khouri, MD | Phase 2 | CCC |
Siltuximab Jack Khouri, MD | Phase 2 | CCC |
Same molecule, other indications
Anakinra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →